Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital

Criteria

Inclusion Criteria:

• 18-65 years

• histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressive lymphoma such as lymphoblastic lymphoma and Burkitt lymphoma)

• plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± Rituximab (R)

• KPS ≥70

• plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles of treatment for neutropenia prophylactic treatment

• absolute neutrophil count≥1.5×109/L，platelet count ≥100× 109/L，hemoglobin≥90g/L，while blood cell count≥3.0×109/L，without bleeding signs

• adquate liver and renal function as protocol discribed

• no serious cardiovascular disease as protocol discribed

• under good mental conditions and informed consented

• potential benefit for subjects based on investigators' decision

Exclusion Criteria:

• history of hematopoetic stem cell transplantationor organ transplantation

• uncontrollable infection

• allergic to study drugs or ingredients

• accepted any other investigational drug or participated another interventional study within 30 days during screening period

• other uncontrollable conditions judged by the investigator

• breast-feeding , pregnant or plan to be pregnant during study observation period